Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

被引：1
|
作者：
Santos, Allan de Souza
Santos, Herbert Henrique de Melo
Salvino, Marco Aurelio
Silva, Sarah Queiroz
Lucas, Larissa Ferreira
Almeida, Alessandro de M.
Santos, Mariane Melo
Santos, Juliana Andrade
Hungria, Vania T. M.
Arruda, Maria da Gloria B.
Torres, Alex
Crusoe, Edvan De Queiroz
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141438
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Shune, Leyla
    Badros, Ashraf
    Chari, Ajai
    Richardson, Paul G.
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    Hoehn, Daniela
    Lin, Thomas S.
    Voorhees, Peter M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S308 - S309
  • [42] CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: INITIAL RESULTS OF A PHASE 1 STUDY
    Bringhen, S.
    Musto, P.
    Gay, F.
    Giuliani, N.
    Liberati, A. M.
    Pautasso, C.
    Ponticelli, E.
    De Paoli, L.
    Zambello, R.
    Ciccone, G.
    Carella, A. M.
    Boccadoro, M.
    Sonneveld, P.
    Palumbo, A.
    HAEMATOLOGICA, 2016, 101 : 520 - 520
  • [43] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
    Mehra, Maneesha
    Cote, Sarah
    Kampfenkel, Tobias
    Nair, Sandhya
    BLOOD, 2019, 134
  • [44] Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
    Hulin, Cyrille
    Offner, Fritz
    Moreau, Philippe
    Roussel, Murielle
    Belhadj, Karim
    Benboubker, Lotfi
    Caillot, Denis
    Facon, Thierry
    Garderet, Laurent
    Kuhnowski, Frederique
    Stoppa, Anne-Marie
    Kolb, Brigitte
    Tiab, Mourad
    Jie, Kon-Siong
    Westerman, Matthijs
    Lambert, Jerome
    Pei, Lixia
    Vanquickelberghe, Veronique
    de Boer, Carla
    Vermeulen, Jessica
    Kampfenkel, Tobias
    Sonneveld, Pieter
    van de Donk, Niels W. C. J.
    HAEMATOLOGICA, 2021, 106 (08) : 2257 - 2260
  • [45] Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone plus /- daratumumab induction regimen
    Meseha, Mina
    Abusamra, Murad
    Farooki, Azeez
    Derkach, Andriy
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Shah, Urvi
    Lu, Sydney
    Mailankody, Sham
    Patel, Dhwani
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Lesokhin, Alexander
    Korde, Neha
    Giralt, Sergio
    Usmani, Saad
    Tan, Carlyn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S139 - S140
  • [46] Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Anderson, Larry D.
    Nathwani, Nitya
    Shah, Nina D.
    Efebera, Yvonne A.
    Costello, Caitlin L.
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2019, 134
  • [47] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sara A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Lutska, Yana
    Bobba, Padma
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter M.
    BLOOD, 2021, 138
  • [48] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sara A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Lutska, Yana
    Bobba, Padma
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter M.
    BLOOD, 2020, 136
  • [49] Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone
    Horigome, Yuichi
    Kamata, Hirotoshi
    Michishita, Yusuke
    Yokoyama, Maki
    Tadera, Noriyuki
    Hayama, Kei
    Suzuki, Takahiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
  • [50] Impact of Daratumumab (DARA) administration during transplant-eligible newly diagnosed Multiple Myeloma (TE NDMM) induction on stem cell (SC) mobilization count and post-transplant engraftment
    Crusoe, Edvan
    Almeida, Alessandro
    Chaves, Marcos
    Salvino, Marco
    Nicanor, Jamile
    Leal, JOanna
    Santos, Herbert
    Santos, Allan
    Guimaraes, Victor
    Dourado, Daniela
    Lucas, Larissa
    Santos, Mariane
    Santos, Juliana
    Arruda, Maria da Gloria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S131 - S131
12345